Search

Your search keyword '"Pieber, Thomas R."' showing total 926 results
Start Over Author "Pieber, Thomas R." Language english
926 results on '"Pieber, Thomas R."'

5. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Ludvik, Bernhard, Prager, Rudolf, Paulweber, Bernhard, Ebenbichler, Christoph F, Keymeulen, B, De Block, C, Grossman, Loren, Houlden, Robyn, Perron, Patrice, Ransom, Thomas, Senior, Peter, Weisnagel, S. John, Woo, Vincent, Dumas, Richard, Thompson, David, Vilsbøll, Tina, Gram, Jeppe, Juhl, Claus Bogh, Hukkanen, Janne, Lahtela, Jorma, Niskanen, Leo, O'Shea, Donal, O'Brien, Timothy, Sreenan, Seamus, Wainstein, Julio, Phillip, Moshe, Knobler, Hilla, Dotta, Francesco, Piatti, Pier Marco, Roberto, Trevisan, Gnasso, Agostino, Gulseth, Hanne, Cooper, John, Pankowska, Ewa, Lukaszewicz, Monika, Wolnik, Bogumił, Manita, Isabel, Marques, Olinda, Roque, Cristina, Príncipe, Rosa Maria, Neves, Celestino, Heitor, Susana, Ruyatkina, L, Dvoryashina, Irina, Vagapova, Gulnar, Belousova, Lidiya, Sergeeva-Kondrachenko, Marina, Peskov, Andrey, Frolova, Elena, Golovach, Albina, Kunitsyna, Marina, Krasnopeeva (Kabachkova), Natalia, Ipatko, Irina, De la Cuesta, Carmen, Tinahones, Francisco José, Rigla, Mercedes, Merino, Juan Francisco, Gómez, Luis Alberto, Fernández, Mercè, Simó, Rafael, Rydén, Mikael, Jendle, Johan, Filipsson, Karin, Eliasson, Björn, Mankovsky, Borys, Lymar, Iurii, Sokolova, Liubov, Myshanych, Galyna, Zlova, Tetiana, Vlasenko, Maryna, Kuskalo -, Petro, Courtney, Hamish, Dayan, Colin, English, Patrick, Heller, Simon, Johnson, Andrew B, Nair, Sunil, Leslie, R. D, Narendran, P, Oliver, Nick, Ramtoola, Shenaz, Shaw, Jim, Viljoen -, Adie, Al-Karadsheh, Amer, Dostou, Jean Marie, Gangi, Sumana, Gottlieb, Peter, Jerkins, Terri, Magnotti, Michael, Marks, Jennifer, Nakhle, Samer, Bonabi, Gholamreza, Myers, Lyle, Pratley, Richard, Hagopian, William, Pettus, Jeremy, von Scholten, Bernt Johan, Wesley, Johnna D, Kreiner, Frederik F, von Herrath, Matthias, Bain, Stephen C, Bode, Bruce, Clausen, Jesper Ole, Coppieters, Ken, Gaysina, Leylya, Gumprecht, Janusz, Hansen, Troels Krarup, Mathieu, Chantal, Morales, Cristobal, Mosenzon, Ofri, Segel, Stine, Tsoukas, George, and Pieber, Thomas R

Published
2021
Full Text
View/download PDF

6. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial.

Author

Sourij, Caren, Oulhaj, Abderrahim, Aziz, Faisal, Tripolt, Norbert J., Aberer, Felix, Pferschy, Peter N., Postula, Marek, Drexel, H., Benedikt, Martin, Kolesnik, Ewald, Pieber, Thomas R., Bugger, Heiko, von Lewinski, Dirk, and Sourij, Harald

Subjects
SODIUM-glucose cotransporters, MYOCARDIAL infarction, SODIUM-glucose cotransporter 2 inhibitors
Abstract

The article discusses a study that examined the effects of empagliflozin, a medication used to treat diabetes, on heart function in patients who had a heart attack. The study found that the medication had similar effects on heart function regardless of the patients' blood sugar levels. The results are consistent with previous research showing the benefits of empagliflozin in heart failure patients. However, more research is needed to fully understand the long-term effects of the medication in heart attack patients. The study was funded by a grant and the authors have no conflicts of interest. [Extracted from the article]

Published
2024
Full Text
View/download PDF

7. Study protocol for assessing the user acceptance, safety and efficacy of a tablet-based workflow and decision support system with incorporated basal insulin algorithm for glycaemic management in participants with type 2 diabetes receiving home health care: A single-centre, open-label, uncontrolled proof-of-concept study

Author

Libiseller, Angela, Kopanz, Julia, Lichtenegger, Katharina M., Mader, Julia K., Truskaller, Thomas, Lackner, Bettina, Aberer, Felix, Pandis, Marlene, Reinisch-Gratzer, Johanna, Ambrosch, Gisela C., Sinner, Frank, Pieber, Thomas R., and Donsa, Klaus

Published
2020
Full Text
View/download PDF

8. Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation

Author

Moschovaki Filippidou, Foteini, Kirsch, Alexander H., Thelen, Matthias, Kétszeri, Máté, Artinger, Katharina, Aringer, Ida, Schabhüttl, Corinna, Mooslechner, Agnes A., Frauscher, Bianca, Pollheimer, Marion, Niedrist, Tobias, Meinitzer, Andreas, Drucker, Daniel J., Pieber, Thomas R., Eller, Philipp, Rosenkranz, Alexander R., Heinemann, Akos, and Eller, Kathrin

Published
2020
Full Text
View/download PDF

13. Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans

Author

Stekovic, Slaven, Hofer, Sebastian J., Tripolt, Norbert, Aon, Miguel A., Royer, Philipp, Pein, Lukas, Stadler, Julia T., Pendl, Tobias, Prietl, Barbara, Url, Jasmin, Schroeder, Sabrina, Tadic, Jelena, Eisenberg, Tobias, Magnes, Christoph, Stumpe, Michael, Zuegner, Elmar, Bordag, Natalie, Riedl, Regina, Schmidt, Albrecht, Kolesnik, Ewald, Verheyen, Nicolas, Springer, Anna, Madl, Tobias, Sinner, Frank, de Cabo, Rafael, Kroemer, Guido, Obermayer-Pietsch, Barbara, Dengjel, Jörn, Sourij, Harald, Pieber, Thomas R., and Madeo, Frank

Published
2019
Full Text
View/download PDF

14. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Author

Akın, S, Aladağ, N, Arif, A A, Aronne, L J, Aronoff, S, Ataoglu, E, Baik, S H, Bays, H, Beckett, P L, Berker, D, Bilz, S, Bode, B, Braun, E W, Buse, J B, Canani, L H S, Cho, Y M, Chung, C H, Colin, I, Condit, J, Cooper, J, Delgado, B, Eagerton, D C, El Ebrashy, I N, El Hefnawy, M H M F, Eliaschewitz, F G, Finneran, M P, Fischli, S, Fließer-Görzer, E, Geohas, J, Godbole, N A, Golay, A, Gorban de Lapertosa, S, Gross, J L, Gulseth, H L, Helland, F, Høivik, H O, Issa, C, Kang, E S, Keller, C, Khalil, S H A, Kim, N H, Kim, I J, Klaff, L J, Laimer, M, LaRocque, J C, Lederman, S N, Lee, K-W, Litchfield, W R, Manning, M B, Mertens, A, Morawski, E J, Murray, A V, Nicol, P R, O'Connor, T M, Oğuz, A, Ong, S, Özdemir, A, Palace, E M, Palchick, B A, Pereles-Ortiz, J, Pieber, T, Prager, R, Preumont, V, Riffer, E, Rista, L, Rudofsky, G, Sarı, R, Scheen, A, Schultes, B, Seo, J A, Shelbaya, S A, Sivalingam, K, Sorli, C H, Stäuble, S, Streja, D A, T'Sjoen, G, Tetiker, T, Van Gaal, L, Vercammen, C, Warren, M L, Weinstein, D L, Weiss, D, White, A, Winnie, M, Wium, C, Yavuz, D, Pieber, Thomas R, Bode, Bruce, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Wallenstein, Signe O R, and Buse, John B

Published
2019
Full Text
View/download PDF

19. Effects of vitamin D supplementation on FGF23: a randomized-controlled trial

Author

Trummer, Christian, Schwetz, Verena, Pandis, Marlene, Grübler, Martin R., Verheyen, Nicolas, Gaksch, Martin, Zittermann, Armin, März, Winfried, Aberer, Felix, Steinkellner, Julia, Friedl, Claudia, Brandenburg, Vincent, Voelkl, Jakob, Alesutan, Ioana, Obermayer-Pietsch, Barbara, Pieber, Thomas R., Tomaschitz, Andreas, and Pilz, Stefan

Published
2019
Full Text
View/download PDF

22. Incidence of Diabetes Mellitus and Its Impact on Outcomes in Patients Undergoing Surgical Pancreatectomy for Non-Malignant and Malignant Pancreatobiliary Diseases—A Retrospective Analysis.

Author

Schranz, Anna, Sternad, Christoph, Aziz, Faisal, Wagner, Doris, Kornprat, Peter, Sucher, Robert, Jost, Philipp J., Wölfler, Albert, Pieber, Thomas R., Sourij, Harald, Riedl, Jakob M., and Aberer, Felix

Subjects
PANCREATECTOMY, DIABETES, PEOPLE with diabetes, PANCREATIC diseases, SURGICAL excision, CANCER relapse
Abstract

Diabetes mellitus (DM) is a prominent risk factor for malignant and non-malignant pancreatic diseases. Furthermore, the presence of DM predicts an unfavourable outcome in people with pancreatic cancer. This retrospective observational study investigated 370 patients who underwent pancreatic resection surgery for various indications (84.3% in malignant indication) in a single surgery centre in Graz, Austria. The preoperative and postoperative diabetes statuses were evaluated according to surgery method and disease entity and predictors for diabetes development after surgery, as well as outcomes (survival and cancer recurrence) according to diabetes status, were analysed. In the entire cohort, the postoperative diabetes (postopDM) incidence was 29%. PostopDM occurred significantly more frequently in malignoma patients than in those with benign diseases (31.3% vs. 16.7%; p = 0.040, OR = 2.28). In the malignoma population, BMI, longer surgery duration, and prolonged ICU and hospital stay were significant predictors of diabetes development. The 1- and 2-year follow-ups showed a significantly increased mortality of people with postopDM in comparison to people without diabetes (HR 1-year = 2.02, p = 0.014 and HR 2-years = 1.56, p = 0.034). Local cancer recurrence was not influenced by the diabetes status. Postoperative new-onset diabetes seems to be associated with higher mortality of patients with pancreatic malignoma undergoing pancreatobiliary surgery. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes.

Author

Pieber, Thomas R., Asong, Marisse, Fluhr, Gabriele, Höller, Vera, Kristensen, Niels R., Larsen, Jonas H., Ribel‐Madsen, Rasmus, Svehlikova, Eva, Vinther, Siri, Voortman, Margarete, and Haahr, Hanne

Subjects
*TYPE 2 diabetes, *INSULIN derivatives, *PHARMACOKINETICS, *INSULIN, *GLUCOSE clamp technique, *BODY mass index, *BLOOD sugar
Abstract

Aims: To characterize the pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in type 2 diabetes (T2D). Materials and Methods: In an open‐label trial, 46 individuals with T2D (18‐75 years; body mass index 18.0‐38.0 kg/m2; glycated haemoglobin ≤75 mmol/mol [≤9%]; basal insulin‐treated) received subcutaneous once‐weekly icodec for ≥8 weeks at individualized doses, aiming at a pre‐breakfast plasma glucose concentration of 4.4 to 7.0 mmol/L (80‐126 mg/dL) on the last three mornings of each weekly dosing interval. Frequent blood sampling to assess total serum icodec concentration (ie, albumin‐bound and unbound) occurred from first icodec dose until 35 days after last dose. Icodec trough concentrations following initiation of once‐weekly dosing were predicted by pharmacokinetic modelling. During the final 3 weeks of icodec treatment, while at steady state, the icodec glucose‐lowering effect was assessed in three glucose clamps (target 7.5 mmol/L [135 mg/dL]): 0 to 36, 40 to 64 and 144 to 168 h post‐dose, thus covering the initial, middle and last part of the 1‐week dosing interval. Glucose‐lowering effect during a complete dosing interval was predicted by pharmacokinetic‐pharmacodynamic modelling. Results: Model‐predicted icodec steady state was attained after 3 to 4 weeks. At steady state, model‐predicted daily proportions of glucose‐lowering effect on days 1 to 7 of the 1‐week dosing interval were 14.1%, 16.1%, 15.8%, 15.0%, 14.0%, 13.0% and 12.0%, respectively. Icodec duration of action was at least 1 week in all participants. Once‐weekly icodec was overall safe and well tolerated in the current trial. Conclusions: The pharmacokinetic and pharmacodynamic characteristics of icodec in individuals with T2D support its potential as a once‐weekly basal insulin. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. The flavonoid 4,4′-dimethoxychalcone promotes autophagy-dependent longevity across species

Author

Carmona-Gutierrez, Didac, Zimmermann, Andreas, Kainz, Katharina, Pietrocola, Federico, Chen, Guo, Maglioni, Silvia, Schiavi, Alfonso, Nah, Jihoon, Mertel, Sara, Beuschel, Christine B., Castoldi, Francesca, Sica, Valentina, Trausinger, Gert, Raml, Reingard, Sommer, Cornelia, Schroeder, Sabrina, Hofer, Sebastian J., Bauer, Maria A., Pendl, Tobias, Tadic, Jelena, Dammbrueck, Christopher, Hu, Zehan, Ruckenstuhl, Christoph, Eisenberg, Tobias, Durand, Sylvere, Bossut, Noélie, Aprahamian, Fanny, Abdellatif, Mahmoud, Sedej, Simon, Enot, David P., Wolinski, Heimo, Dengjel, Jörn, Kepp, Oliver, Magnes, Christoph, Sinner, Frank, Pieber, Thomas R., Sadoshima, Junichi, Ventura, Natascia, Sigrist, Stephan J., Kroemer, Guido, and Madeo, Frank

Published
2019
Full Text
View/download PDF

41. Nucleocytosolic Depletion of the Energy Metabolite Acetyl-Coenzyme A Stimulates Autophagy and Prolongs Lifespan

Author

Eisenberg, Tobias, Schroeder, Sabrina, Andryushkova, Aleksandra, Pendl, Tobias, Küttner, Victoria, Bhukel, Anuradha, Mariño, Guillermo, Pietrocola, Federico, Harger, Alexandra, Zimmermann, Andreas, Moustafa, Tarek, Sprenger, Adrian, Jany, Evelyne, Büttner, Sabrina, Carmona-Gutierrez, Didac, Ruckenstuhl, Christoph, Ring, Julia, Reichelt, Wieland, Schimmel, Katharina, Leeb, Tina, Moser, Claudia, Schatz, Stefanie, Kamolz, Lars-Peter, Magnes, Christoph, Sinner, Frank, Sedej, Simon, Fröhlich, Kai-Uwe, Juhasz, Gabor, Pieber, Thomas R., Dengjel, Jörn, Sigrist, Stephan J., Kroemer, Guido, and Madeo, Frank

Published
2014
Full Text
View/download PDF

42. Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy

Author

Barnard, Katharine D., Wysocki, Timothy, Ully, Vanessa, Mader, Julia K., Pieber, Thomas R., Thabit, Hood, Tauschmann, Martin, Leelarathna, Lalantha, Hartnell, Sara, Acerini, Carlo L., Wilinska, Malgorzata E., Dellweg, Sibylle, Benesch, Carsten, Arnolds, Sabine, Holzer, Manuel, Kojzar, Harald, Campbell, Fiona, Yong, James, Pichierri, Jennifer, Hindmarsh, Peter, Heinemann, Lutz, Evans, Mark L., and Hovorka, Roman

Published
2017
Full Text
View/download PDF

45. Cover Image, Volume 19, Issue 10

Author

Ruan, Yue, Thabit, Hood, Leelarathna, Lalantha, Hartnell, Sara, Wilinska, Malgorzata E., Tauschmann, Martin, Dellweg, Sibylle, Benesch, Carsten, Mader, Julia K., Holzer, Manuel, Kojzar, Harald, Evans, Mark L., Pieber, Thomas R., Arnolds, Sabine, and Hovorka, Roman

Published
2017
Full Text
View/download PDF

46. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.

Author

Heller, Simon, Battelino, Tadej, Bailey, Timothy S., Pieber, Thomas R., Hövelmann, Ulrike, Plum‐Mörschel, Leona, Melgaard, Anita E., Aronson, Ronnie, DiMeglio, Linda A., Johansen, Thue, and Danne, Thomas

Subjects
TYPE 1 diabetes, HYPOGLYCEMIA, BLOOD sugar, DEATH rate, GLUCAGON, RESCUE work
Abstract

Aims: To perform an integrated analysis of the safety and efficacy of dasiglucagon, a glucagon analogue available in a ready‐to‐use aqueous formulation, to treat severe hypoglycaemia (SH) in type 1 diabetes (T1D). Materials and Methods: An integrated analysis of dasiglucagon safety was conducted on data from two placebo‐controlled trials (placebo‐controlled pool) and two placebo‐controlled and four non‐placebo‐controlled trials (broad pool) in adults with T1D. An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo‐controlled and two non‐placebo‐controlled trials in adults with T1D. Results: Dasiglucagon had a similar safety and tolerability profile to that of reconstituted glucagon. In the placebo‐controlled datasets, no serious adverse events (AEs), AEs leading to withdrawal from the trial, or deaths were reported. The most common causally related AEs were nausea (56.5%) and vomiting (24.6%). The broad pool safety analysis showed similar results. Dasiglucagon efficacy in time to plasma glucose recovery from insulin‐induced SH was similar to that of reconstituted glucagon (median 10.0 and 12.0 minutes, respectively) and superior to placebo (median 40.0 minutes; P < 0.0001). The median recovery time was consistent across all placebo‐controlled trial subgroups. Conclusions: Dasiglucagon was well tolerated and effective as a rapid rescue agent for insulin‐induced SH in people with T1D. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Urinary C- Peptide to Creatinine Ratio (UCPCR) as Indicator for Metabolic Risk in Apparently Healthy Adults—A BioPersMed Cohort Study.

Author

Reintar, Sharmaine, Pöchhacker, Magdalena, Obermayer, Anna, Eberhard, Katharina, Zirlik, Andreas, Verheyen, Nicolas, von Lewinski, Dirk, Scherr, Daniel, Hutz, Barbara, Haudum, Christoph W., Pieber, Thomas R., Sourij, Harald, and Obermayer-Pietsch, Barbara

Abstract

Background: C-peptide is produced in equimolar amounts with insulin from pancreatic beta cells, and thus is a fundamental biomarker for beta cell function. A non-invasive urinary C-peptide-to-creatinine ratio (UCPCR) has attracted attention as a biomarker for metabolic conditions. However, the UCPCR as an indicative risk predictor for prediabetes is still being investigated. Methods: We aimed to characterize UCPCRs in healthy people using American Diabetes Association (ADA) criteria and to evaluate their metabolic outcomes over time. A total of 1022 participants of the Biomarkers in Personalized Medicine cohort (BioPersMed) were screened for this study. Totals of 317 healthy with normal glucose metabolism, 87 prediabetic, and 43 diabetic subjects were included. Results: Prediabetic participants had a significantly higher UCPCR median value than healthy participants (p < 0.05). Dysglycaemia of healthy baseline participants was measured twice over 4.5 ± 0.9 years; 25% and 30% were detected with prediabetes during follow-ups, predicted by UCPCR both for the first (p < 0.05) and the second visit (p < 0.05), respectively. This is in good agreement with the negative predictive UCPCR value of 60.2% based on logistic regression. UCPCR levels were equal in both sexes. Conclusion: UCPCR measurements provide an indicative approach for metabolic risk, representing a potential use for prevention and monitoring of impaired glucose metabolism. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes.

Author

Svehlikova, Eva, Ashcroft, Nicole L., Gatschelhofer, Christina, Gerring, David, Höller, Vera, Jezek, Jan, Lackner, Bettina, Lawrence, Fiona, Pillai, Vijay, Ratzer, Maria, Urschitz, Martina, Wolf, Michael, and Pieber, Thomas R.

Subjects
INSULIN aspart, TYPE 1 diabetes, PHARMACODYNAMICS, PHARMACOKINETICS, INSULIN therapy
Abstract

OBJECTIVE: To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 U500) compared with insulin aspart (IAsp U100). RESEARCH DESIGN AND METHODS: This single-center, randomized, double-blind study was conducted in 38 men with type 1 diabetes (body weight ≤100 kg and total insulin dose <1.2 units/kg/day). Participants received a single dose of either AT278 U500 or IAsp U100 (0.3 units/kg s.c.) in a crossover design, followed by an 8-h euglycemic clamp in the absence of basal insulin. RESULTS: With AT278 U500, onset of appearance in serum was 6 min earlier (P < 0.0001) and reached 50% of maximum concentration 23 min faster (P < 0.0001). Insulin exposure with AT278 U500 was 4.0-fold higher within the first 30 min (95% CI 3.29, 4.90), 1.5-fold higher within the first 60 min (95% CI 1.35, 1.76), and statistically superior up to 90 min postdose (P < 0.05). With AT278 U500, onset of action was 10 min earlier (P < 0.0001) and reached 50% of maximum glucose infusion rate 20 min faster (P < 0.0001). The glucose-lowering effect with AT278 U500 was 8.9-fold higher within the first 30 min (95% CI 5.96, 17.46), 2.4-fold higher within the first 60 min (95% CI 1.92, 3.22), and statistically superior up to 2 h postdose (P < 0.0001). Overall insulin exposure and glucose-lowering effect were comparable. No significant safety findings were observed. CONCLUSIONS: AT278 U500 offers rapid-acting characteristics in a reduced dose volume, with accelerated absorption and onset of action compared with IAsp U100 in the studied population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. The effect of high-dose cholecalciferol on bioavailable vitamin D levels in critically ill patients: a post hoc analysis of the VITdAL-ICU trial

Author

Martucci, Gennaro, Tuzzolino, Fabio, Arcadipane, Antonio, Pieber, Thomas R., Schnedl, Christian, Urbanic Purkart, Tadeja, and Treiber, Gerlies

Subjects
Alfacalcidol, Calcifediol, Vitamin D, Health care industry
Abstract

Author(s): Gennaro Martucci [sup.1], Fabio Tuzzolino [sup.2], Antonio Arcadipane [sup.1], Thomas R. Pieber [sup.3], Christian Schnedl [sup.4], Tadeja Urbanic Purkart [sup.5], Gerlies Treiber [sup.3], Karin Amrein [sup.3] Author Affiliations: (1) [...]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results